Neurocrine Biosciences’ Post

View organization page for Neurocrine Biosciences, graphic

58,487 followers

We are pleased to announce the U.S. FDA has accepted our two New Drug Applications (NDAs) with a Priority Review designation for an investigational treatment of classic congenital adrenal hyperplasia (CAH) in children, adolescents and adults. Read more: https://lnkd.in/g2pVurx3

  • No alternative text description for this image
Kristie Wallace

Pharmacy Industry Expert and Practitioner

1w

This is exceptional news for patients and families living with CAH everyday.. my hope would be it also helps to bridge care across the patient lifespan!

Eryn Johnson

Human Resources Manager specializing in Benefits Administration, and Organizational Effectiveness

1w

This is amazing news! As a mother of 2 w/ classic CAH we are looking forward to a different treatment!!

Like
Reply
Bradley Weinstein

Executive Director @ Cytel | Global AOD Sales, Data Science Leader

1w

Amazing!! Congratulations to the whole team at Neurocrine Biosciences! I know how much hard work has gone into this and this is a huge win for the patients & families of those living with CAH!

Like
Reply
Pragnesh Donga, RAC

NCE | Biosimilars | Regulatory Strategy | Global Regulatory Affairs

1w

This is amazing news! Congratulations

Like
Reply
Lisette McLaughlin

𝐏𝐫𝐢𝐧𝐜𝐢𝐩𝐚𝐥 | 𝐅𝐨𝐮𝐧𝐝𝐞𝐫 | 𝐄𝐱𝐞𝐜𝐮𝐭𝐢𝐯𝐞 𝐏𝐚𝐫𝐭𝐧𝐞𝐫 | 𝐂𝐇𝐈𝐄𝐅 𝐌𝐞𝐦𝐛𝐞𝐫

1w

This is great news for patients and the team!! Congrats!

Like
Reply
Muhammad Haseeb, PhD

Senior Scientist (Computational Chemistry) | Bioinformatician | Autoimmune & Inflammatory diseases

1w

Congratulations, wish you all the best

Like
Reply
Darren Nelson 🚀 (We're hiring)

Innovative Leadership in Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies.

1w

🎉 Congratulations, Neurocrine Biosciences team! This is fantastic news on the acceptance of your NDAs for the treatment of congenital adrenal hyperplasia. Looking forward to the positive impact this will have on patients. 🌟 #FDA #NewDrugApplication #HealthcareInnovation

Like
Reply
Kevin Draper

Sr. Director Business Development, Strategic Accounts-West Coast at WuXi Biologics

1w

Fantastic, and congrats sir! wish you well! kd

Like
Reply
Iyad Alrabadi, M.S, PMP, CEM

Executive Director, Leader of West Coast Operations at Genesis AEC

5d

This is great news. Congrats!

Joel F. Cooper, PhD, DABT, ERT

Director, Toxicology at Neumora Therapeutics, Inc.

1w

Fantastic news all.

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics